Olmesartán/Amlodipino/Hidroclorotiazida Stada (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipine/Hydrochlorothiazide is used in the management of hypertension, targeting multiple pathways that control blood pressure.

• Hypertension: lowers systolic and diastolic pressure when monotherapy does not achieve target levels.
• Resistant hypertension: provides additional control in patients who need more than one class of antihypertensive.
• Cardiovascular risk reduction: contributes to lowering the risk of stroke and myocardial infarction associated with high blood pressure.

• The combination works through three complementary mechanisms: olmesartan blocks the angiotensin II type‑1 receptor, reducing vasoconstriction and aldosterone release; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide promotes renal sodium and water excretion, decreasing plasma volume. Together these actions produce additive blood‑pressure reduction.

Adverse reactions may occur with any antihypertensive combination therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Peripheral edema
• Fatigue
• Cough
• Increased urination

Serious or Rare Side Effects

• Severe hypotension
• Electrolyte disturbances (e.g., low potassium)
• Acute kidney injury
• Angio‑edema
• Liver enzyme elevation
• Blood cell abnormalities

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

• Renal impairment: adjust monitoring of kidney function and electrolytes.
• Hepatic disease: use with caution; monitor liver enzymes.
• Electrolyte imbalance: watch for potassium and sodium levels.
• Pregnancy: avoid use; teratogenic risk is unknown.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Olmesartan/Amlodipine/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal failure.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function.
• Lithium: may increase lithium levels, risking toxicity.
• Antidiabetic agents: may enhance hypoglycaemia; monitor glucose.
• Alcohol: additive blood‑pressure lowering effect; advise moderation.